by author Novel approaches towards HBV cure
|
|
- Ernest Abraham Ryan
- 5 years ago
- Views:
Transcription
1 Jörg Petersen Liver Unit IFI Institute at Asklepios Klinik St. Georg University of Hamburg Germany Novel approaches towards HBV cure New horizons in Hepatitis B,D, and E, ECCMID, Madrid, 24 April 2018
2 Disclosures Grant/research support: Bristol-Myers Squibb, Novartis, Roche Clinical studies: AbbVie, Arrowhead, Bristol-Myers Squibb, Eisai, Falk, Gilead Sciences, Hepatera, Hologic, Intercept, Janssen, Merck Sharp & Dohme, Roche, Siemens, Vertex Consultant/advisor: Abbott, AbbVie, Arrowhead, Assembly Pharma, Bristol-Myers Squibb, Contravir, Gilead Sciences, GlaxoSmithKline, Janssen, Kedrion, Merck Sharp & Dohme, Novira, Roche Sponsored lectures: Abbott, Bristol-Myers Squibb, Boehringer, Gilead Sciences, Janssen, Kedrion, Merck Sharp & Dohme, Merz, Novartis, Roche
3 Achievements and ongoing challenges Hepatitis B: From a treatable disease to a curable disease? Decrease hepatic inflammation and fibrosis Liaw YF, et al. N Engl J Med 2004;351: ; Marcellin P, et al. Lancet 2013;381: Dandri M, Petersen J. Clin Infect Dis 2016;62:281-8 Suppression of HBV replication Prevent/reduce complications of cirrhosis,reduction of HCCs Very good safety (10yrs) Hepatitis B treatment NA or PEG-IFN No HBV cure Will this become achievable in the future? S8JP14
4 Considerations for current tretment options Hepatitis B: From a treatable disease to a curable disease? Unlike in HCV drug development there is a very effective and safe therapy available which suppresses HBV DNA - generic ETV and TDF (and TAF as new NA player) On the global scale, people are still suffering from complications of chronic Hepatitis B and dying in large numbers because they do not receive any therapy in many parts of the world S8JP14
5 Globally, an estimated 250 million people are infected with HBV Region, ( % prevalence of HBsAg) African region (3.0) Region of the Americas (0.2) Eastern Mediterranean region (1.6) European region (0.4) South-East Asian region (0.7) Western Pacific region (0.9) It is estimated that 15 million people in Europe are living with HBV WHO. Global hepatitis report Available at: (accessed November 2017) HBsAg: hepatitis B surface antigen
6 HBV: Considerations for Current tretment options From a treatable disease to a curable disease? The HBV field remains complicated: Endpoints are currently being discussed Large number of new therapeutic targets and possible combination therapies especially at this years EASL meeting April 2018 in Paris have been presented Large pharmaceutical companies navigate back toward HBV with new drug combinations S8JP14
7 Why do our current treatment options not result in complete cure? cccdna pgrna AAA AAA Dandri M, Petersen J: Hepatitis B Virus DNA clearance: Killing for curing? Hepatology 2005;42:1453-8, Allweiss et al, Gut 2017 HBV NTCP Subgenomic RNAs AAA cccdna not affected by NA and not efficiently affected by PEG-IFN
8 What does cure of HBV mean? Several definitions are used Liver Achieved with NUCs Blood Nucleos(t)ide analogueinduced virus suppression (HBeAg seroconversion=20%) Virus suppression Modified from Durantel D, et al. J Hepatol 2016;64:S Achieved with IFN-based and NA therapy in a small proportion of patients Liver Blood Decreased viral RNA and protein synthesis, HBsAg loss +/- seroconversion Functional cure Liver Elimination of cccdna but persistence of integrated viral DNA Complete cure Blood Currently unachievable Sterilising cure cccdna: covalently closed circular DNA; HBeAg: hepatitis B e antigen
9 Overall transplant-free survival (%) Cumulative incidence of hepatocellular carcinoma (%) Why is functional HBV cure important? If you cannot kill HBV, inactivate the disease as much as possible HBsAg loss improves survival and lowers HCC incidence in patients who are currently on oral antiviral therapy Kim GA, et al. Gut 2014;63: HBsAg seroclearance (n=93) No HBsAg seroclearance (n=372) P=0.02 HR 0.10; 95% CI Time after treatment initiation (years) HBsAg seroclearance (n=93) No HBsAg seroclearance (n=372) P<0.01 HR 0.06; 95% CI Time after treatment initiation (years) CI: confidence interval; HCC: hepatocellular carcinoma; HR: hazard ratio
10 HBsAg loss as endpoint of CHB therapy HBsAg loss with, or without, anti-hbs seroconversion, is an optimal endpoint The ultimate goal would be achievement of HBsAg loss with a finite course of oral antiviral therapy Immune control of the disease is important the role of flares is being debated But: In HBeAg negative patients, HBsAg may be produced from integrated DNA too and not exclusively from cccdna EASL. J Hepatol 2017;67:370 98, Wooddell CI et al, Wooddell C, et al. Sci Transl Med 2017 Sep 27 doi: /scitranslmed.aan0241
11 NA discontinuation before HBsAg loss a new concept? Really? Recommendation: Discontinuation of NAs in selected non-cirrhotic HBeAg-negative patients who have achieved long-term (3 years) virological suppression under NA(s) may be considered if close post-na monitoring can be guaranteed. In some parts of the world, due to restricted budget situation limited duration of therapy with NAs is already part of some guidelines (APASL) EASL. J Hepatol 2017;67:370 98, APASL Hepatol Intern 2016;10:1-98
12 New HBV targets what pathways or approaches might we take? Stimulation of innate and / or adaptive immunity Targeting cccdna preclinical stage Petersen J, et al. J Hepatol 2016;65: Entry inhibitors RNA interference (sirna) Capsid assembly modulators Inhibition of HBsAg release
13 Safety, pharmacokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ (JNJ-6379) in treatment-naive CHB patients without cirrhosis Aim: Evaluate safety, PK, and antiviral activity of multiple ascending doses of novel CAM JNJ-6379 in CHB pts Zoulim F, et al. EASL 2018, Paris. #LBO-004 NVR GLS4-JHS JNJ-6379 Company J & J HEC Pharma J & J Dose 60 mg QD 120 mg QD 240 mg QD 25 mg QD / 75 mg QD 150 mg QD Mean DNA reduction (log) Mean RNA reduction (log) 0.86 NA NA Other CpAM in development include: ABI-H0731; ABI-H2158; ABI-Nx; SBA-R01; AB-423; AB-506; GLP-26 Session 8 (8 drug; 4 placebo) Session 9 (8 drug; 4 placebo) Session 10 (9 drug; 3 placebo) 100 mg QD 75 mg QD 150 mg QD 25 mg QD 8-week follow-up 8 week follow-up 8 week follow-up 0 1 Dosing period (days) 28 Follow-up phase 84
14 Mean (SD) HBV DNA change from BL (log 10 IU/mL) Safety, pharmacokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ (JNJ-6379) in treatment-naive CHB patients without cirrhosis Baseline characteristics ITT analysis Zoulim F, et al. EASL 2018, Paris. #LBO mg QD (n=12)* 75 mg QD (n=12)* 150 mg QD (n=12)** Mean age, years (SD) 39.5 (11.6) 36.5 (10.2) 45.8 (9.9) Sex Male, n (%) 11 (92) 10 (83) 9 (75) Race White, n (%) 6 (50) 12 (100) 10 (83.3) ALT Grade, n (%) Grade 0 9 (75) 9 (75) 9 (75) Grade 1 3 (25) 3 (25) 3 (25) Metavir fibrosis stage n, (%) F0 4 (33) 5 (42) 5 (42) F1 6 (50) 4 (33) 7 (58) F2 2 (17) 3 (25) 0 HBeAg positive, n (%) 6 (50) 3 (25) 0 Mean HBV DNA log 10 IU/mL (SD) 6.41 (1.99) 5.36 (1.54) 4.84 (1.43) Mean HBsAg log 10 IU/mL (SD) 4.07 (0.96) 3.95 (0.55) 3.91 (0.70) HBV genotype D, n (%) 5 (42) 10 (83) 8 (67) *Sessions 8 and 9: JNJ-6379 (n=8); PBO (n=4) **Session 10: JNJ-6379 (n=9); PBO (n=3) including one pt with recombinant genotype C/D Mean HBV DNA change from BL up to 4 weeks f/u Pooled PBO (n=11) f/u period Time (weeks) 25 mg (n=8) 75 mg (n=8) 150 mg (n=9) Each * refers to 1 pt with HBV DNA <LLQ * *** *** *** **** *** ** * n=9 n=8 n=5 n=3 **
15 Safety, pharmacokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ (JNJ-6379) in treatment-naive CHB patients without cirrhosis Pharmacokinetics Following repeat administration, exposure increased in a dose-dependent manner Safety On-treatment AEs (28 days) Zoulim F, et al. EASL 2018, Paris. #LBO-004 Session 8 25 mg (n=8) Session 9 75 mg (n=8) Session mg (n=9) Pooled placebo (n=11) At least one AE 5 (63) 4 (50) 6 (67) 7 (64) Worst reported grade of AE, n (%) Grade 1 3 (38) 2 (25) 3 (33) 5 (46) Grade 2 1 (13) 1 (13) 2 (22) 2 (18) Grade 3 1 (13) 1 (13) * 0 0 Grade (11) 0 SAEs, n (%) ** 0 AEs leading to treatment discontinuation (%) (11) 0 JNJ-6379 (administered for 28 days) was generally well tolerated and resulted in potent antiviral activity at all doses evaluated Data warrant additional evaluation of compound in Phase 2a * 1 pt had isolated Gr1 and 2 ALT and Gr 1 AST elevations on treatment that raised to Gr3 and 4 ALT and Gr3 AST elevations during f/u, without other lab changes or clinical symptoms; ** 1 SAE observed during f/u: right frontal lobe mass, unrelated to study drug; 1 pt receiving 150 mg JNJ-6379 QD had isolated ALT/AST elevation without any other lab changes or clinical symptoms
16 Durable inhibition of HBV replication and antigenemia using a subcutaneously administered sirna agent in preclinical models ARB-1467: RNA interference product (IV) with a 3-trigger design inhibiting HBV replication, reducing HBV transcripts, and lowering HBV antigens, delivered via proprietary lipid nanoparticle (LNP) technology (P2) Here second generation preclinical: AB-729: Novel RNA interference agent (SC), N-acetylgalactosamine (GalNAc) conjugate liver targeting technology, pan-genotypic activity, multi-month duration of surface antigen inhibition after a single SC dose, 10-fold larger dose for HBsAg reduction Lee A, et al. EASL 2018, Paris. #PS-029 sirna delivery is mediated by a conjugated targeting ligand; GalNAc Cell uptake via GalNAc interaction with ASGPR Asialoglycoprotein Receptor Highly expressed in/on hepatocytes High rate of uptake 15 min recycling time Conserved across species
17 S e r u m H B s A g ( L o g I U / m L ) Durable inhibition of HBV replication and antigenemia using a subcutaneously administered sirna agent in preclinical models Asialoglycoprotein receptor interaction demonstrated in vitro (PHH or immortalized hepatocytes) dose sirna Weeks W e e k s after A f t e r Oone n e S C SC D odose s e Lee A, et al. EASL 2018, Paris. #PS-029 Analyzed expanded panel panel of HBV of markers at Day 14 (right HBV panel, markers & next slide) at Day 14 L L O Q S a l i n e 1 m g / k g 3 m g / k g 9 m g / k g Clear dose response, achieved max effect detectable in this model Supports clinical dosing frequency of 1 month (or more) Controls Liver sections stained for HBsAg 200 µm 729 Treatment
18 Serum S e r u m HBsAg H B s A g (log IU/mL) (L o g IU / m L ) Durable inhibition of HBV replication and antigenemia using a subcutaneously administered sirna agent in preclinical models Log L O G inhibition In h ib itio n # # L iv e r 3.5 k b H B V R N A Inhibition h it ioof n omultiple f M u le HBV H B V markers M a r k e r s bby y ' L iv e r T o ta l H B V R N A Next generation sirna agent with long half-life, SC route, demonstrating suppression of replication and reduction of antigenemia Lee A, et al. EASL 2018, Paris. #PS-029 L iv e r H B s A g S e r u m H B s A g 14 days after single dose treatment in AAV mice (mean of n=5 ±SD) # relative to baseline (serum readouts) or saline control (liver readouts) *indicates signal for 1 animal below LLOQ * S e ru m H B e A g C o n tro l s ir N A 9 m g / k g ' m g / k g ' m g / k g ' m g / k g * S e ru m H B V D N A * * AB-729 has longer duration of activity than ARB Weeks W e e k s after A r administration A d m is a tio n Ain A V AAV M ic emice Dose responsive effects on all measured HBV markers cccdna not significantly present in this model; not expected to be directly impacted by RNAi Next step: Safety studies L L O Q S a lin e A R B , 0.3 m g / k g IV A B , 3 m g / k g S C
19 New HBV targets what pathways or approaches might we take? Innate Cytokine therapy, IFN TLR agonists (TLR7, TLR8) RIG-I agonists Adaptive Therapeutic vaccine Checkpoint inhibitors (PD-1, PD-L1) Petersen J, et al. J Hepatol 2016;65: Stimulation of innate and / or adaptive immunity (Partial) immune restoration through inhibition of viral antigens
20 Pros and cons of novel approaches to HBV cure Entry inhibitors RNA interference Capsid assembly modulators Immune modulators cccdna impairment Pros Prevents HBV spreading from human hepatocytes in vivo Slows amplification of the cccdna pool by blocking the dynamics of hepatocyte infection Liver-specific reduction in HBV replication and protein expression demonstrated Might show benefit of reducing expression of cccdna and core proteins Dysregulate or inhibit pgrna encapsidation and/or nucleocapsid assembly Oral, combo therapies Cons Lack of data Most interest for HBV/HDV at this stage Parenteral Next speaker will talk about HDV Sustainability of response still to be demonstrated antibodies? Parenteral, second generation sc not iv anymore Potential for systemic effects and resistance Evidence of efficacy and tolerability Potential for systemic effects, animal models do not necessarily reflect potential and/or safety profile in humans May be able to destroy or damage the major HBV transcriptional template Revill P, et al. Nat Rev Gastroenterol 2016;13:239 48; Durantel D, et al. J Hepatol 2016;64:S117 31; Petersen J, et al. J Hepatol 2016;65: Challenging to identify small molecules Currently at the preclinical stage so safety profile needs to be established
21 Considerations for current tretment options Hepatitis B: From a treatable disease to a curable disease? The HBV field remains complicated: Endpoints are currently being discussed Large number of new therapeutic targets and possible combination therapies Probably different therapies for different subpopulations of patients (no one fits all therapies) New biomarker needed to measure success (DNA suppressed patient on NA followed by add-on CPAM) Becoming more invasive again? (Biopsies in subsets of patients in phase 2 studies) S8JP14
22 Invasive biomarker and the need for biopsies cccdna As a key molecule of the viral life cycle, cccdna represents the major target for next-generation therapeutics Besides questions in respect to cccdna dynamics and standardisation, HBV infection of the liver is likely to become increasingly heterogenous during long-term infection and antiviral treatment o Q: does a small biopsy reflect the whole liver? Furthermore, we need to balance the benefits vs risks with this invasive procedure Chi H, et al. Eur J Gastroenterol Hepatol 2017;29:36 41 Liver biopsies are not without a risk for the patient 5.6% complications (pain, bleeding) 1.7% severe (hospitalisation >2 days, intervention needed) 0.06% of patients died (1/1806)
23 Circulating viral antigens and particles Adapted from Lucifora J, Protzer U. Hepatitis B Virus X Protein: A Key Regulator of the Virus Life Cycle. Available at: (accessed November 2017)
24 (Novel) HBV serum markers qhbsag (established) HBcrAg Circulating viral RNAs HBcrAg: hepatitis core-related antigen
25 Quantitative HBsAg tests total HBsAg Abbott linear range IU/mL Elecsys linear range ,000 IU/mL Abbot linear range , ,000 1,000,000 HBsAg Level (IU/mL) Zacher BJ, et al. Clin Vaccine Immunol 2011;18: Package insert: Elecsys HBsAg II quant Elecsys linear range Linear ranges covering clinically relevant HBsAg levels
26 HBV RNA (pgrna) in circulating viral particles First described in 1996 in the serum of infected patients Can be released into serum as enveloped 3.5kb pregenomic RNA containing virions Amount of circulating pgrna strongly correlates with the amount of pgrna present in the whole liver and with transcriptionally active cccdna in humanised mice Marker to study the transcriptional activity of cccdna Wang J, et al. J Hepatol 2016;65:700 10; Giersch K, et al. J Hepatol 2017;66:460 2; Butler K, et al. AASLD 2017; Poster #1915 No commercially available test yet, but performance of an automated prototype assay for the detection and quantification of hepatitis B pregenomic RNA in chronic HBV patients receiving nucleo(t)side analogue therapy
27 Serum HBV pgrna can serve as clinical marker for cccdna activity with HBV mono and HBV/HDV co-infection (in humanised mice and patients) HBV-monoinfection (+/- IFN-treatment) HBV/HDV-coinfection DNA RNA Allweiss L, et al. ILC 2017; Poster #SAT-176; Giersch K, et al. J Hepatol 2017;66:460 2 IFN-treated untreated IFN-treated
28 Serum HBV pgrna can serve as clinical marker for cccdna activity with HBV mono and HBV/HDV co-infection (in humanised mice and patients) HBV-monoinfection (+/- IFN-treatment) HBV/HDV-coinfection Allweiss L, et al. ILC 2017; Poster #SAT-176; Giersch K, et al. J Hepatol 2017;66:460 2 DNA RNA IFN-treated untreated IFN-treated IFN lowers levels of pgrna in serum; very good correlations between serum pgrna and intrahepatic pgrna (=cccdna activity) but not with cccdna amounts in mice treated with IFN (due to reduced cccdna activity) or in HDV coinfected mice
29 How to use these markers? Petersen J, et al. J Hepatol 2016;65:835 48
30 The problem of suboptimal HBV-DNA suppression Several recent studies demonstrated persistence of HBV-DNA or intrahepatic HBV- DNA synthesis during NA treatment, although qpcr showed undetectable DNA levels No prevention of cccdna synthesis from incoming virus/replenishment Combo NA plus CpAMs (sirna): Expect to improve inhibition of viral genomes within hepatocytes But how to measure here efficacy if biopsies unavailable? pgrna? HBcrAg? Boyd A, et al. J Hepatol 2016;65:683 91; Petersen J, personal opinion CpAM: core protein allosteric modifier
31 HBV: Considerations for Current tretment options From a treatable disease to a curable disease? The HBV field remains complicated: What are the correct populations with HBV to be treated? Easiest to show an effect? Patient with highest need? Inactive carriers / Immunotolerant patients NUC suppressed patients Challenging times ahead of us S8JP14
32 Summary Ultimate goal in management of CHB is to completely cure the virus Currently, only a small proportion of patients will achieve functional cure (HBsAg loss); complete virological cure is still not possible Knowledge of the HBV replication cycle has resulted in identification of new agents that may have the potential to (functionally) cure more HBV patients in the future Today s view is that combining new treatment targets appears to be necessary to achieve higher rates of functional cure in the future Demonstration of the long-term safety profile of all new treatment targets is of utmost importance With new therapies comes need to proof success of treatment HBcrAg and HBV mrna
33 Jörg Petersen Liver Unit IFI Institute at Asklepios Klinik St. Georg University of Hamburg Thank you for your attention
HBV Novel Therapies Maria Buti MD, PhD
HBV Novel Therapies Maria Buti MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital CONFLICT OF INTEREST I have financial relationships to disclose within the past 12 months relevant
More informationThe HBV pipeline and what the SIG can offer
The HBV pipeline and what the SIG can offer Current treatments and definition of cure Where can we get to with current therapies? Special interest group possibilities Where are we headed with HBV cure
More informationHepatitis B New Therapies
Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth
More informationHepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement
Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationRNA Interference: A New Tool in the Toolbox for Treatment of HBV. Discovery On Target Senior Director, Research 25 September 2017
RNA Interference: A New Tool in the Toolbox for Treatment of HBV Amy Lee Discovery On Target Senior Director, Research 25 September 2017 Arbutus Biopharma Boston, MA NASDAQ: ABUS www.arbutusbio.com Chronic
More informationHBV Cure Definition and New Drugs in Development
HBV Cure Definition and New Drugs in Development Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada
More informationWhy do we need new HBV treatment and what is our definition for cure?
Why do we need new HBV treatment and what is our definition for cure? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationAre Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationHBV Treatment Pipeline: Prospects for a Cure. Marion Peters, MD UCSF San Francisco, CA
HBV Treatment Pipeline: Prospects for a Cure Marion Peters, MD UCSF San Francisco, CA HBV Control Inflammatory: normalize serum ALT, biopsy Virologic: decrease HBV DNA Immune: seroconversion HBeAg to anti-hbe
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationALN-HBV. Laura Sepp-Lorenzino November 11, Alnylam Pharmaceuticals, Inc.
ALN-HBV Laura Sepp-Lorenzino November 11, 2016 2016 Alnylam Pharmaceuticals, Inc. 1 N-Acetyl Galactosamine (GalNAc) sirna Conjugates Subcutaneous Investigational RNAi Therapeutics 5 -sense 5 -AS ASGPR
More informationHBV Cure Overview of Viral and Immune Targets
HBV Cure Overview of Viral and Immune Targets Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada October
More informationUnderstanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development
Understanding HBV Testing: HBsAg, HBV RNA, cccdna, HBeAg and HBcrAg in Context of Antiviral Drug Development Professor Stephen Locarnini WHO Regional Reference Centre for Hepatitis B Victorian Infectious
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More information4th International HIV/Viral Hepatitis Co-Infection Meeting
4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationTreatment of chronic hepatitis delta Case report
Treatment of chronic hepatitis delta Case report George Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National and Kapodistrian University of Athens, Director of Academic Department
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationRNAi Therapy for Chronic HBV Infection
RNAi Therapy for Chronic HBV Infection Bill Symonds, PharmD Chief Development Officer October 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationHepatitis D. Challenges in 2018
Hepatitis D Challenges in 2018 Heiner Wedemeyer Essen University Hospital, Germany Germany Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie, Abivax, BMS, Boehringer Ingelheim,
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationWhats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen
Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?
More informationInarigivir: A novel RIG-I agonist for chronic hepatitis B
: A novel RIG-I agonist for chronic hepatitis B Stephen Locarnini, Danny Wong, Kathy Jackson, Renae Walsh, Ros Edwards, Rachel Hammond, Carla S. Coffin, Magdy Elkhashab, Susan Greenbloom, Alnoor Ramji,
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationHepatitis B: is there still a role for interferon?
16 January 2018 Hepatitis B: is there still a role for interferon? Pietro Lampertico Gastroenterology and Hepatology Division Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of Milan
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationSERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca
SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca Louis Jansen 1,2, Andrew Vaillant 3, Karel van Dort 1, Femke Stelma 1,2, Neeltje
More informationIs There a Best Direct Acting Antiviral Agent for HBV?
Is There a Best Direct Acting Antiviral Agent for HBV? Fabien Zoulim Hepatology Department, Hospices Civils de Lyon INSERM U1052, Cancer Research Center of Lyon Lyon University, France What targets for
More informationSlides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.
Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationManagement of HBV infection between Specialist and General Practitioners
13 October 2016 Management of HBV infection between Specialist and General Practitioners Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico
More informationCurrently status of HBV therapy: efficacy and limitations
9 November 2016 Currently status of HBV therapy: efficacy and limitations Pietro Lampertico Gastroenterology and Hepatology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico University of
More information6/9/2015. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Director, Schiff Center for Liver Diseases University of Miami
Grant/Research Support: AbbVie, BMS, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen, Discovery Life Sciences, Beckman Coulter, Inc., Siemens Corporation, MedMira Inc., Conatus Eugene R.
More informationHepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationHepatitis B (and D) Cure Strategies: How far are we?
Hepatitis B (and D) Cure Strategies: How far are we? Heiner Wedemeyer Dept. of Gastroenterology and Hepatology Essen University Hospital International Hepatitis E Symposium February 14-16, 2019 H. Wedemeyer
More informationMF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9
SB 9200 (Inarigivir), an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from cohort 1 of the ACHIEVE Trial MF Yuen 2, CS Coffin 3, M Elkhashab
More informationHBV Forum pre-easl 2018
HBV Roadmap Update from Recent and EASL Presentations HBV Forum pre-easl 2018 Robert G Gish MD Adjunct Professor Stanford University Medical Director HB Foundation See robertgish.com Disclosures Introduction
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationSB9200: A Novel and Efficacious RIG-I Agonist for Chronic Hepatitis B: Results from cohort 1 of the ACHIEVE Trial
SB9200: A Novel and Efficacious RIG-I Agonist for Chronic Hepatitis B: Results from cohort 1 of the ACHIEVE Trial Stephen Locarnini 2, Danny Wong 3, Kathy Jackson 2, Renae Walsh 2, Ros Edwards 2, Rachel
More informationHBeAg-negative chronic hepatitis B. with a nucleos(t)ide analogue?
4 th PARIS HEPATITIS CONFERENCE HBeAg-negative chronic hepatitis B Why do I treat my chronic hepatitis B patients with a nucleos(t)ide analogue? George V. Papatheodoridis, MD 2nd Department of Internal
More informationDiscontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection
Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection Dr Abid Suddle Institute of Liver Studies King s College Hospital Why consider discontinuation of NA therapy?
More informationEffects of Inarigivir (SB9200) Therapy on Immune Responses in Patients with Chronic Hepatitis B (CHB)
Effects of (SB9200) Therapy on Immune Responses Patients with Chronic Hepatitis B (CHB) Renae Walsh 1, Rachel Hammond 1, Kathy Jackson 1, Ros Edwards 1, Chelsea Macfarlane 2, Radhakrishnan P. Iyer 2, Man
More informationTargeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates Richard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationThe Evolution of sirna Therapeutics Targeting HBV at Arrowhead Pharmaceuticals. Sept 25, 2018
The Evolution of sirna Therapeutics Targeting HBV at Arrowhead Pharmaceuticals Sept 25, 2018 Disclosures I am an employee and shareholder in Arrowhead Pharmaceuticals, Inc. Safe Harbor Statement This presentation
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationArbutus Biopharma Corporation, Burnaby, Canada.
HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in Positive and Negative Virally Suppressed Patients With Hepatitis B Kosh Agarwal 1, Ed Gane 2, Wendy Cheng
More informationRichard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations
Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates Richard Colonno Executive Vice President and Chief Scientific Officer of Virology Operations 1 CAUTIONARY NOTE REGARDING FORWARD-
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationNew Drug Research for Chronic Hepatitis B Man-Fung Yuen, MD, PhD
New Drug Research for Chronic Hepatitis B Man-Fung Yuen, MD, PhD Department of Medicine. The University of Hong Kong, Queen Mary Hospital, Hong Kong OVERVIEW Emerging Drugs against HBV Direct-acting antiviral
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationHepatitis Delta. Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain
Hepatitis Delta Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain Disclosures Member of speaker bureau and advisory board for: Roche, Boehringer, Gilead, Viiv,
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationABC of Viral Hepatitis. Mark Thursz
ABC of Viral Hepatitis Mark Thursz Disclosures Research funding Affimmune Gilead GSK Novartis Vital Therapies Advisory Boards / Speaker Fees Affimmune Norgine Novartis Gilead HAV HAV Naked RNA virus Picornavirus
More informationMedInform. HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders. Original Article
HBsAg-guided extension of Peg-IFN therapy in HBeAg-negative responders Nina Nikolova, Deian Jelev, Krassimir Antonov, Lyudmila Mateva, Zahariy Krastev. University Hospital St. Ivan Rilski Sofia, Clinic
More informationHepatitis B Virus Treatment: 2017 Newcomers
Clinical Hepatology Update Clinical Hepatology Update Hepatitis B Virus Treatment: 2017 Newcomers Sang Hoon Ahn Department of Internal Medicine, Institute of Gastroenterology, Yonsei Liver Center Brain
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationHepatitis delta: often forgotten?
15 th Annual Resistance and Antiviral Therapy Meeting Dr Sarah Hughes King s College Hospital, London Thursday 29 September 2011, Royal College of Physicians, London Hepatitis delta: often forgotten? Dr
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationDelta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne
Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment
More informationAssembly Biosciences, Inc. Corporate Presentation. March 2018 Nasdaq: ASMB
Assembly Biosciences, Inc. Corporate Presentation March 2018 Nasdaq: ASMB Cautionary Note Regarding Forward-Looking Statements The information in this presentation contains estimates and other forward-looking
More information23 ε Γηεκερίδα Ιογελώλ Ηπαηηηίδωλ Β θαη C «Ση. Χαηδεγηάλλες» 30 θαη 31 Ιαλοσαρίοσ 2016
23 ε Γηεκερίδα Ιογελώλ Ηπαηηηίδωλ Β θαη C «Ση. Χαηδεγηάλλες» 30 θαη 31 Ιαλοσαρίοσ 2016 Λεηηοσργηθή θαη Ιοιογηθή Ιαζε ηες Χρολίας Ηπαηίηηδας Β: Παρόλ θαη Μέιιολ Σηέθαλος Χαηδεγηάλλες Οκόηηκος Καζεγεηής
More informationNovel targets for HBV therapy
VHPB Meeting Hot Topics in Prevention and Control of Viral Hepatitits Lisbon, 15-16th March 2018 Novel targets for HBV therapy Barbara Testoni, PhD Cancer Research Center of Lyon INSERM UMR1052, CNRS 5286
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationKey to Therapeutic Success in HBV
Abstract # PS-027 Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452,
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationA Leading HBV Therapeutics Company. Corporate Overview August 2017
A Leading HBV Therapeutics Company Corporate Overview August 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements within the meaning of
More informationDisclosures. Grant: Arrowhead Pharmaceuticals
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen Man-Fung Yuen * 1, Kevin
More informationModeling Kinetics of HBV Infection and Recommendations for Moving Forward
Modeling Kinetics of HBV Infection and Recommendations for Moving Forward Alan S. Perelson Theoretical Biology and Biophysics Los Alamos National Laboratory Los Alamos, NM HBV Models Hepatology 1999 Tsiang
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More information